BTG (LON:BTG) had its price target decreased by equities researchers at JPMorgan Chase from GBX 750 ($10.53) to GBX 680 ($9.55) in a research report issued to clients and investors on Friday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase’s price target would indicate a potential upside of 11.93% from the stock’s current price.
BTG has been the subject of several other reports. Numis Securities reaffirmed a “buy” rating and issued a GBX 900 ($12.63) price target on shares of BTG in a research note on Friday, December 8th. Shore Capital upgraded shares of BTG to a “buy” rating in a report on Monday, March 26th. Finally, Peel Hunt reiterated a “hold” rating and set a GBX 700 ($9.83) price objective on shares of BTG in a report on Wednesday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of GBX 774.71 ($10.87).
BTG opened at GBX 607.50 ($8.53) on Friday. BTG has a 1-year low of GBX 559.82 ($7.86) and a 1-year high of GBX 784 ($11.01).
ILLEGAL ACTIVITY WARNING: “BTG (BTG) PT Lowered to GBX 680” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/btg-btg-pt-lowered-to-gbx-680.html.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.